In 2023, the hospital discharges for leiomyoma of the uterus in the UK were reported at 50 units per hundred thousand persons. From 2024 onward, the data forecasts a declining trend, with a year-on-year decrease: 2024 (48.9), 2025 (48.1), 2026 (47.2), 2027 (46.4), and 2028 (45.5). This represents an average annual decline of approximately 1.5% over the five-year period.
Future trends to watch for include potential changes in medical treatment protocols for uterine fibroids and demographic shifts that could affect hospital discharge rates. Monitor innovations in non-invasive procedures and policy changes in healthcare delivery.
